Pay in 4 interest-free payments of $7.11 Learn more
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17
Published clinical research evaluating Retatrutide and triple hormone receptor agonists
These agents leverage multi-agonist receptor targeting for superior outcomes, demonstrating up to a 2.5% greater reduction in HbA1c
Tirzepatide is called a dual incretin because it acts on both GIP and GLP-1 receptors
Note: Always consult with a licensed healthcare professional before starting any new supplement while on prescription medication
You can read the full article at Tirzepatide (TZP), a new dual GIP/GLP-1 receptor agonist for treating type 2 diabetes (T2D), displayed superior outcomes in HbA1c reduction and patients achieving target levels compared to semaglutide and titrated insulin degludec across 40-weeks (SURPASS-2) and 52-weeks (SURPASS-3) studies
US$ 26.20
&srotate=0)
US$ 28.48
&srotate=0)
US$ 24.95
US$ 24.39
US$ 21.51
US$ 29.13
US$ 20.69
